Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innocan Pharma Corp C.INNO

Alternate Symbol(s):  INNPF

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of... see more

Recent & Breaking News (CSE:INNO)

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

Canada NewsWire June 11, 2024

Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million

Canada NewsWire May 27, 2024

FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain

Canada NewsWire May 21, 2024

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Canada NewsWire May 9, 2024

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Canada NewsWire April 22, 2024

Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M

Canada NewsWire April 1, 2024

Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.

Canada NewsWire March 25, 2024

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million

Canada NewsWire March 14, 2024

Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study

Canada NewsWire March 5, 2024

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Canada NewsWire February 26, 2024

Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024

Canada NewsWire February 20, 2024

Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST

Canada NewsWire February 5, 2024

Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration

Canada NewsWire December 12, 2023

Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from a prolong use in animals

Canada NewsWire November 3, 2023

Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research

Canada NewsWire October 23, 2023

Innocan Pharma Announces Closing of Second and Final Tranche of Financing

Canada NewsWire October 20, 2023

Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update

Canada NewsWire October 12, 2023

Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million

GlobeNewswire September 21, 2023

Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board

Canada NewsWire September 15, 2023

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

Canada NewsWire September 5, 2023